Al-Eidan

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?

Fahad A S Al-Eidan

College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Kingdom of Saudi Arabia 

Corresponding author: Dr. Fahad A S Al-Eidan, Assistant Professor, College of Medicine, King Saud bin Abdulaziz University for Health Sciences. PO Box 22490, Riyadh 11426, Kingdom of Saudi Arabia. Mobile: 00966506414425. E-mail: faleidan@yahoo.com  

Published: April 20, 2015,
Received: January 18, 2015
Accepted: March 13, 2014
Mediterr J Hematol Infect Dis 2015, 7(1): e2015029, DOI 10.4084/MJHID.2015.029
This article is available on PDF format at:

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Background. The increasing trend of using low-molecular-weight-heparin (LMWH) versus unfractionated heparin (UFH) in hospitalized adult patients is raising concerns about the incidence of heparin-induced thrombocytopenia (HIT).
Method. A retrospective study analyzed the requests for heparin-induced antibodies by enzyme-linked immunosorbent assay (ELISA) among adult hospitalized patients during the period from January 2011 to December 2013. These patients received either UFH or LMWH for prevention or therapeutic indications. Those with positive immune-mediated HIT were identified and considered as case patients.
Result. The usage of LMWH and UFH and development of HIT was determined during the study period. The incidence of HIT in patients receiving UFH and those receiving LMWH was 4.09 per thousand patients and 0.48 per thousand patients, respectively, (p<0.0001) with an overall incidence of 2.49 per thousand patients.
Conclusion. The increased trend of using LMWH over UFH among hospitalized adult patients was observed and can be said to contribute to the diminished overall incidence of HIT.

Introduction

Venous thromboembolism (VTE) is the most common preventable cause of hospital morbidity and mortality. A preventative pharmacological agent is recommended for all hospitalized patients at risk of developing VTE. Low-molecular-weight-heparin (LMWH) and unfractionated heparin (UFH) are widely used and cost effective VTE prevention agents.[1,2]  However, heparin-induced thrombocytopenia (HIT) is an immune-mediated, potentially life-threatening adverse effect of heparin therapy.[3,4] Heparin can  induce immunoglobulin G (IgG) antibodies production against itself and platelet factor 4 (PF4); the antibodies stimulate platelets and endothelial cells, resulting in an excess production of thrombin, inducing thrombocytopenia and thromboembolic events.[5-7] HIT occurs in approximately 3% of patients who receive UFH and approximately 0.2% of patients who receive LMWH.[4,8-11]
HIT is clinically diagnosed by a drop in platelet count to less than 100X109/L or a 50% decrease in platelets after the initiation of heparin therapy with no apparent explanation other than HIT.[12] A positive laboratory test for HIT antibodies supports this clinical diagnosis. The development of HIT can be either; delayed-onset, typically 5 to14 days after the initial administering of heparin, or rapid-onset, occurring soon after the re-administering of heparin to a patient with prior heparin exposure and HIT antibodies.[7,13,14]
Heparin exposure has a unique HIT complication that is characterized by a defined thrombocytopenia and immune-mediated platelet activation that can lead to thrombin over-production and increase the chance of developing VTE in the majority of patients. This can lead to life-threatening complications.[15,16
A retrospective database analysis was performed on the annual incidence of HIT at a single teaching center. We assessed the effect of prescribing UFH and LMWH, with additional analysis of the annual lab requests for HIT antibodies and confirmed positive HIT tests

Methods

Data from The King Abdulaziz Medical City, (KAMC) Riyadh, Saudi Arabia, were used to conduct a retrospective study. The following characteristic data were extracted from patient’s medical record: age, gender, admitting services, indication of heparin administration, and type of heparin.
All patients aged at least 18 years who were admitted to the hospital between January 1, 2011, and December 31, 2013, and who received LMWH or UFH at prevention or therapeutic doses during admission, were reviewed. Enoxaparin was the only LMWH on KAMC Formulary during the study period. First admission in which the diagnosis of HIT occurred was only considered in patients with multiple readmissions. The main clinical suspicion parameter was the platelet count, determined as follows: pretreatment platelet count at baseline, and then every 2 to 3 days from commencing UFH or LMWH administration for first two weeks.
Thrombocytopenia was defined as a platelet count fall of ≥50% from a baseline that was apparent by HIT diagnosis based on clinical probability which routinely evaluated according to the 4Ts score system by the hematology services. The origin of thrombocytopenia was confirmed by the detection of serum heparin-induced antibodies, using a commercial enzyme-linked immunosorbent assay (ELISA) for IgG, IgA, and IgM class antibodies (Asserachrom HPIA, Diagnostica Stago, Asniere sur Seine, France).[1,24,25] All HIT positive patients were diagnosed and labeled by hematology services. ELISA was performed in the KAMC hematology laboratory according to manufacturer's procedures. HIT results expressed in optical density (OD) units and a value of >0.4 was considered to be positive according to the manufacturer's range. Exclusion criteria were as follows: (1) patients who developed HIT or thrombocytopenia before the study period and still in the hospital during the study period. (2) Heparin or its derivatives given after the thrombocytopenia occurred. (3) Thrombocytopenia explained by other conditions such as a chemotherapeutic agent being administered. From this data, the annual number of patients who received UFH or LMWH for prevention or therapeutic indications and the total number of heparin-induced antibody assays performed over the study period was determined.
Identified HIT patients were divided into three groups: (1) patients receiving LMWH; (2) patients receiving UFH; and (3) total number of patients receiving LMWH and UFH. The incidence of HIT was determined for each group, and the HIT incidence trend was also determined over the study period.The relative risk was calculated by comparing patients exposed to UFH and those exposed to LMWH for prevention or therapeutic indications.
Statistical analysis. Data was summarized as means (S.D) or proportions. Cumulative incidence rate and 95% confidence interval (CI) was calculated per one thousand patients. Comparison between incidence rates was conducted using a chi-square test. All tests were two-sided and a P value < 0.05 was considered significant. The STATA statistical software (STATACORP, TX, USA, version 11) was used to carry out the statistical analysis.


Results

The main clinical, demographic characteristics of the 116 patients who developed HIT including sex, age, indication, admitting hospital department, and laboratory results are summarized in Table 1

Table1 Table 1. Main demographic characteristics of the study group.

Sixty-seven patients were male, and 49 were female. The mean (±SD) age was 64 (±16). UFH for prevention indication (65.5%) was used more frequently than LMWH. The mean (±SD) platelet nadir was 82 (±18). The majority of HIT patients (62.1%) had a high clinical the 4Ts score. ELISA assays were reported and classified by OD values. HIT patients were associated with a decreased albumin level (Mean ±SD; 25±7).
Table 2 describes the annual development of HIT in our data from January 2011 to December 2013. In patients receiving UFH and those receiving LMWH, the annual incidence rate of HIT per one thousand patients was 4.42 and 0.46 in 2011 (P<0.0001); 4.19 and 0.47 in 2012 (P<0.0001); 3.48 and 0.50 in 2013 (P<0.0001), respectively, with an over 3-year incidence of 4.09 and 0.48 (P<0.0001) respectively. The patients who received UFH were 8.5 times more likely to develop HIT than those who received LMWH. 

Table2 Table 2. Annual incidence rates of HIT per one thousand patients.

A decrease in the total annual incidence rate of HIT, UFH and LMWH, was observed: 3.24 in 2011, 2.62 in 2012 and 1.72 in 2013 (Figure 1).The difference in the incidence of HIT between 2011 and 2012 was not statistically significant (difference=0.63, 95%CI -0.67 to 1.92, P=0.32). Similarly the difference between 2012 and 2013 was not statistically significant (difference=0.90, 95%CI -0.19 to 1.99, P=0.08). However the difference between the incidence in 2011 and 2013 was statistically significant (difference=1.53, 95%CI 0.36 to 2.71, P=0.006). 

Figure 1
Figure 1. Trends in the incidence rates of HIT per 1000 patients from 2011 to 2013 and the total over a three-year study period incidence rate. Each bar represents incidence rate and confidence intervals.

The annual number of hospitalized patients who received heparin (UFH and LMWH) and the number of HIT assays performed with HIT test results are summarized in Table 3. Briefly, the number of patients who received UFH decreased from 10,175 patients (70%) in 2011 to 6,890 (40%) in 2014, while the number of patients who received LMWH increased from 4,309 patients (30%) in 2011 to 9,989 (59) in 2014. The total number of patients who received heparin (UFH or LMWH) increased from 14,484 patients in 2011 to 16,879 in 2014. However, the total annual HIT assays performed decreased by 48 % from 953 tests in 2011 to 462 in 2014. The annual number of patients receiving LMWH inversely correlated with annual number of HIT assays performed (Figure 2A), while the annual number of patients receiving UFH correlated very closely with the annual numbers of HIT assays performed (Figure 2B).

Table3 Table 3. Annual number of hospitalized patients who received heparin and number of HIT assays performed with HIT test results.

Figure 2
Figure 2. Graph ‘A’ shows a correlation between the annual number of patients receiving low molecular weight heparin (LMWH) and annual number of heparin-induced thrombocytopenia (HIT) assays performed. ‘B’ shows the correlation between annual number of patients receiving unfractionated heparin (UFH) and annual numbers of HIT assays.


Discussion

To our knowledge, this is the first study to describe the cumulative incidence rate of HIT in an adult hospitalized Saudi population. This study showed that the cumulative incidence rate of HIT when using UFH was 4.09 per 1,000 patients, and the incidence when using LMWH was 0.48, with the overall cumulative incidence being 2.49. Our incidence is consistent with that of most previously published figures.[4,8,17,18] Similarly, other authors found that LMWH is associated with lower risk of HIT than UFH.[10,11]
A trend towards increasing the annual use of LMWH vs. UFH was observed between 2011 and 2013 (Table 3). Interestingly, the increased use of LMWH during the study period showed a direct impact as the annual incidence rate decreased significantly between 2011 and 2013. (3.24 per one thousand patients vs. 1.72, respectively with P=0.006).
Despite of the annual increase in the number of patients receiving heparin (UFH and LMWH) during the study period, there was a significant decrease in the annual number of requests for heparin-induced antibodies by ELISA between 2011 and 2013. This correlation may be due to the increased use of LMWH over UFH and its low effect on platelet count and may have contributed to our finding. Zhou et al (2012), in a study conducted between 2005 and 2009, observed that despite a doubling in the number of patients receiving pharmacoprophylaxis with heparin, there was no significant increase in the number of consultations for thrombocytopenia, the number of requests for HIT tests, the number of positive HIT test results, or the number of HIT diagnoses. In this period there was a significant increase of proportion of patients treated with LMWH  The number of cases of HIT was low and represented < 0.1% of patients exposed to heparin.[19] Therefore, many authors in previous studies have suggested LMWH as a preferred agent, despite the higher cost per dose, due to a low risk of thrombocytopenia and HIT.[10,11,20-23]
The current study has several limitations such as its retrospective nature, which raises concerns about measured and unmeasured bias that may lead to misclassifying patients who have HIT or not. A further limitation is that a PF4-dependent ELISA was used to detect antibodies against PF4/heparin to confirm the HIT diagnosis. Although functional assays are more specific for detecting HIT antibodies than PF4-dependent ELISA,[1,2,24] an ELISA assay is often used because of its rapid performance, and lower cost compared with a functional test. However, functional tests were not performed in the center where the study was conducted which may have affected the HIT result identification. In addition, outcomes such as complications and survival rate have not been possible to identify accurately, nor was a specific population group targeted in the study.  Finally, concurrent agents that may contribute to the development of thrombocytopenia were not considered except chemotherapy.

.

Conclusion

In this three-year study period, we identified a decreasing incidence rate of HIT in hospitalized adult patients that may be attributed to the increasing use of LMWH over UFH.

References

  1. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:Suppl: e495S-e530S.  
  2. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Br J Haematol 2012;159(5):528-40. 
  3. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101: 3049-51. http://dx.doi.org/10.1182/blood-2002-05-1448 PMid:12506031  .     
  4. Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955-9. http://dx.doi.org/10.1182/blood-2002-07-2201 PMid:12480713   .    
  5. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163(20):2518-2524. http://dx.doi.org/10.1001/archinte.163.20.2518 PMid:14609790  .     
  6. Warkentin TE, Roberts RS, Hirsh J, Kelton JG.Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005;127(5):1857-1861. http://dx.doi.org/10.1378/chest.127.5.1857 PMid:15888871   .    
  7. Greinacher A,Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005;94(1):132-135. http://dx.doi.org/10.1160/TH04-12-0825 
  8. Crowther MA, Cook DJ, Albert M, et al.The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010;25(2):287-293. http://dx.doi.org/10.1016/j.jcrc.2009.12.006 PMid:20149589   .    
  9. Lee GM, Arepally GM.. Diagnosis and management of heparin-induced thrombocytopenia. HematolOncolClin North Am. 2013;27(3):541-63. http://dx.doi.org/10.1016/j.hoc.2013.02.001 PMid:23714311   PMCid:PMC3668315 
  10. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106(8):2710-2715. http://dx.doi.org/10.1182/blood-2005-04-1546 PMid:15985543  .     
  11. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-1335. http://dx.doi.org/10.1056/NEJM199505183322003  PMid:7715641   .    
  12. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163(20):2518-2524. http://dx.doi.org/10.1001/archinte.163.20.2518 PMid:14609790  .     
  13. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355:809-817. http://dx.doi.org/10.1056/NEJMcp052967 PMid:16928996  .     
  14. Warkentin TE. HIT paradigms and paradoxes. J ThrombHaemost 2011;9suppl 1:105-117. http://dx.doi.org/10.1111/j.1538-7836.2011.04322.x  PMid:21781246  .     
  15. Maynard G, Stein J. Designing and implementing effective venous thromboembolism prevention protocols: lesson from collaborative efforts. J Thromb Thrombolysis. 2010;29(2)159-166. http://dx.doi.org/10.1007/s11239-009-0405-4  PMid:19902150  PMCid:PMC2813533 
  16. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch intern Med. 2004;164(4):361-369. http://dx.doi.org/10.1001/archinte.164.4.361 PMid:14980986  .     
  17. Sakr Y. Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care 2011;15: 211. http://dx.doi.org/10.1186/cc9993 PMid:21457505 PMCid:PMC3219407  
  18. Prandoni P, Siragusa S, Girolami B, Fabris F; BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106(9):3049-3054 http://dx.doi.org/10.1182/blood-2005-03-0912 PMid:16030191  .     
  19. Zhou A, Winkler A, Emamifar A, et al. Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis? Chest 2012;142(5):1175-1178. http://dx.doi.org/10.1378/chest.11-2926 PMid:22539642  .     
  20. Wilbur K, Lynd L, Sadatsafavi M. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients-a pharmacoeconomic analysis. Clin Appl Thromb Hemost. 2011;17(5):454-465. http://dx.doi.org/10.1177/1076029610376935 PMid:20699258  .     
  21. Shorr AF, Ramage AS. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. Crit Care Med. 2001;29(9):1659-1665. http://dx.doi.org/10.1097/00003246-200109000-00001  
  22. McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs unfractionated heparin in medical inpatients. Thromb J. 2006;4:17 http://dx.doi.org/10.1186/1477-9560-4-17    PMid:17005045 PMCid:PMC1624807 
  23. Shorr AF, Jackson WL, Weiss BM, Moores LK. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis. Blood Coagul Fibrinolysis. 2007;18(4):309-316. http://dx.doi.org/10.1097/MBC.0b013e328099af58 PMid:17473570  .     
  24. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014;40:106-114. PMid:24363239  .   
  25. ASSERACHROM® HPIA package insert. Diagnostica Stago S.A.S, Asniere sur Seine, France. 2011 

[TOP]

Abstract views:
300

Views:
PDF
122
HTML
1060

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185